Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Accumulated Expenses (2016 - 2025)

Plus Therapeutics has reported Accumulated Expenses over the past 15 years, most recently at $993000.0 for Q4 2025.

  • Quarterly Accumulated Expenses rose 7.93% to $993000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $993000.0 through Dec 2025, up 7.93% year-over-year, with the annual reading at $993000.0 for FY2025, 7.93% up from the prior year.
  • Accumulated Expenses was $993000.0 for Q4 2025 at Plus Therapeutics, up from $920000.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $993000.0 in Q4 2025 and troughed at $781000.0 in Q4 2021.
  • The 5-year median for Accumulated Expenses is $987000.0 (2023), against an average of $934000.0.
  • Year-over-year, Accumulated Expenses grew 26.63% in 2022 and then fell 6.79% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $781000.0 in 2021, then grew by 26.63% to $989000.0 in 2022, then fell by 0.2% to $987000.0 in 2023, then fell by 6.79% to $920000.0 in 2024, then rose by 7.93% to $993000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Accumulated Expenses are $993000.0 (Q4 2025), $920000.0 (Q4 2024), and $987000.0 (Q4 2023).